Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H10FN3O3 |
| Molecular Weight | 227.1924 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](CO)C=C2
InChI
InChIKey=HSBKFSPNDWWPSL-CAHLUQPWSA-N
InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1
| Molecular Formula | C9H10FN3O3 |
| Molecular Weight | 227.1924 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dexelvucitabine is a cytidine analogue, which has been shown to be active in both naive and HIV-experienced individuals and has in vitro activity against a variety of NRTI-resistant strains. Dexelvucitabine belongs to a class of HIV drugs called nucleoside reverse transcriptaseinhibitors (NRTIs). In the Phase IIb study most side effects were generally mild and included headache, fatigue, and gastrointestinal disorders. However, some participants developed severe hyperlipasemia and pancreatitis. Drug development is discontinued due to 40% incidence of grade 4 hyperlipasemia including one case of pancreatitis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C. | 1998 Nov 17 |
|
| Perspectives for the treatment of hepatitis B virus infections. | 1999 Jul |
|
| Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. | 1999 Mar 11 |
|
| Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. | 2001 Jan |
|
| Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies. | 2002 Dec |
|
| Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. | 2002 Dec |
|
| Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. | 2002 Dec |
|
| ViroLogic announces agreement with Achillion. | 2002 Mar |
|
| ACH-126443 Achillion/Yale University. | 2002 Nov |
|
| HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). | 2003 Jan |
|
| Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. | 2003 Jan |
|
| N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity. | 2003 Mar |
|
| Antiretroviral pipeline: new-drug reports from retroviruses conference. | 2004 Feb 27 |
|
| New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. | 2004 Oct |
|
| In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. | 2005 Mar |
|
| Meeting notes from the 3rd IAS Conference. New drugs. | 2005 Oct |
|
| dD4FC development discontinued. | 2006 May |
|
| Elvucitabine data released at CROI. | 2010 Mar |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:37:55 UTC 2023
by
admin
on
Fri Dec 15 16:37:55 UTC 2023
|
| Record UNII |
KU8SPJ271W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C97452
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12470
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
CHEMBL109831
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
C76928
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
64973
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
DTXSID20158678
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
8730
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
DEXELVUCITABINE
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
KU8SPJ271W
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
134379-77-4
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
300000034071
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY | |||
|
QQ-47
Created by
admin on Fri Dec 15 16:37:55 UTC 2023 , Edited by admin on Fri Dec 15 16:37:55 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
